BeiGene (Beijing), Co., Ltd.

Release Summary

BeiGene today announced that it has dosed the first patient in a Phase 1 study of BGB-3111 for the treatment of cancer. BGB-3111 is an investigational, oral, highly selective and potent BTK inhibitor.

BeiGene (Beijing), Co., Ltd.